1.The effects of rosiglitazone on lipid and glucose metabolism,insulin resistance and inflammatory factors in type 2 diabetic patients
Bin HUANG ; Lin LUO ; Wenqun HAN
Chinese Journal of Diabetes 1994;0(01):-
Compared with the 39 cases with T2DM treated by SU+metformin,the 43 T2DM patients treated by SU+metformin+rosiglitazone for 12 weeks had the improved glycemic and lipid profile controls,increased insulin sensitivity,and decreased CRP level(all P
2.A study of effectiveness and safety of insulin glargine in the treatment of patients with type 2 diabetes mellitus
Qiu CHEN ; Wenqun HAN ; Yongbi LIANG ; Qin ZHANG ; Yao LI ; Zhihuang ZUO ; Lisha SUN
Chinese Journal of Postgraduates of Medicine 2012;35(16):4-7
ObjectiveTo investigate the effectiveness and safety of insulin glargine in the treatment of patients with type 2 diabetes mellitus (T2DM),and verify the new remedy called one central and three steps for T2DM.MethodsUsed multicenter,random,open and self-control study.Two hundred and three cases with T2DM treated with insulin glargine were divided into four groups according to different therapy:30 cases with one needle method,106 cases with one needle and one pill method,48 cases with one long-acting and several short-acting method,and 19 cases with one long-acting,one pill and several short-acting method.The changes of blood glucose,glycosylated hemoglobin (HbA1c),weight and so on before and after treatment were observed.ResultsThe levels of fasting plasma glucose(FPG),2 h postprandial plasma glucose (2hPPG) and HbA1c decreased significantly after treatment than those before treatment[(5.78 ±0.76)mmol/L,(8.37 ±:1.37) mmol/L,(6.81 ±0.38)% vs. (11.73 ±4.49) mmol/L,(16.73 ±4.96) mmol/L,(9.43 ± 2.31 )%,P < 0.01 ].The weight and body mass index had no obvious changes before and after treatment( P > 0.05 ).There was significant difference in the level of FPG,2hPPG and HbA1c before and after treatment in four groups respectively(P<0.01 ).There was only 1 case who occurred hypoglycemia during the treatment.ConclusionThe therapy,one central and three steps,is not only effective and safe,but also convenient and cheap for T2DM.
3.Doxorubicin-conjugated siRNA lipid nanoparticles for combination cancer therapy.
Kamila BUTOWSKA ; Xuexiang HAN ; Ningqiang GONG ; Rakan EL-MAYTA ; Rebecca M HALEY ; Lulu XUE ; Wenqun ZHONG ; Wei GUO ; Karin WANG ; Michael J MITCHELL
Acta Pharmaceutica Sinica B 2023;13(4):1429-1437
Evasion of apoptosis is a hallmark of cancer, attributed in part to overexpression of the anti-apoptotic protein B-cell lymphoma 2 (Bcl-2). In a variety of cancer types, including lymphoma, Bcl-2 is overexpressed. Therapeutic targeting of Bcl-2 has demonstrated efficacy in the clinic and is the subject of extensive clinical testing in combination with chemotherapy. Therefore, the development of co-delivery systems for Bcl-2 targeting agents, such as small interfering RNA (siRNA), and chemotherapeutics, such as doxorubicin (DOX), holds promise for enabling combination cancer therapies. Lipid nanoparticles (LNPs) are a clinically advanced nucleic acid delivery system with a compact structure suitable for siRNA encapsulation and delivery. Inspired by ongoing clinical trials of albumin-hitchhiking doxorubicin prodrugs, here we developed a DOX-siRNA co-delivery strategy via conjugation of doxorubicin to the surface of siRNA-loaded LNPs. Our optimized LNPs enabled potent knockdown of Bcl-2 and efficient delivery of DOX into the nucleus of Burkitts' lymphoma (Raji) cells, leading to effective inhibition of tumor growth in a mouse model of lymphoma. Based on these results, our LNPs may provide a platform for the co-delivery of various nucleic acids and DOX for the development of new combination cancer therapies.